S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

Clovis Oncology Stock Price, News & Analysis (NASDAQ:CLVS)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.08
$1.09
52-Week Range
N/A
Volume
1.16 million shs
Average Volume
8.88 million shs
Market Capitalization
$11.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CLVS stock logo

About Clovis Oncology Stock (NASDAQ:CLVS)

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.


CLVS Stock News Headlines

City of Clovis hosts tree lighting ceremony
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Clovis East High School
CLVS.O
CLVSQ Clovis Oncology, Inc.
Clovis Oncology
Boulder drugmaker Clovis Oncology files for bankruptcy
Cancer Focused Clovis Oncology Files For Bankruptcy
See More Headlines
Receive CLVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
12/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CLVS
CUSIP
18946410
Employees
N/A
Year Founded
2009

Profitability

Net Income
$-264,520,000.00
Net Margins
-189.37%
Pretax Margin
-189.68%

Debt

Sales & Book Value

Annual Sales
$148.76 million
Book Value
($2.15) per share

Miscellaneous

Free Float
138,577,000
Market Cap
$11.60 million
Optionable
Optionable
Beta
0.24

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Patrick J. Mahaffy MA (Age 55)
    Co-Founder, Chief Exec. Officer, Pres and Exec. Director
  • Dr. Gillian C. Ivers-Read BSc (Age 64)
    Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations
  • Mr. Daniel W. Muehl CPA (Age 54)
    Sr. VP of Fin. and Principal Financial & Accounting Officer
  • Dr. Lindsey Rolfe BSc (Age 50)
    MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance
  • Mr. Corwin Dale Hooks (Age 51)
    Chief Commercial Officer and Sr. VP














CLVS Stock Analysis - Frequently Asked Questions

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.08. The biopharmaceutical company earned $37.92 million during the quarter, compared to analyst estimates of $38.73 million. During the same period in the previous year, the company posted ($0.89) EPS.

What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO?

12 employees have rated Clovis Oncology Chief Executive Officer Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among the company's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA).

This page (NASDAQ:CLVS) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -